{
    "organizations": [],
    "uuid": "f567cfac7cea78e20d2529cd08875edb5b40dfc0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abbvies-upadacitinib-meets-primary/brief-abbvies-upadacitinib-meets-primary-and-key-efficacy-endpoints-in-phase-2b-3-rheumatoid-arthritis-study-in-japanese-patients-idUSFWN1S20Y9",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In Phase 2B/3 Rheumatoid Arthritis Study In Japanese Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - AbbVie Inc:\n* ABBVIEâ€™S UPADACITINIB MEETS PRIMARY AND KEY EFFICACY ENDPOINTS IN PHASE 2B/3 RHEUMATOID ARTHRITIS STUDY IN JAPANESE PATIENTS\n* ABBVIE INC - SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS, WITH NO NEW SAFETY SIGNALS DETECTED\n* ABBVIE INC - SIGNIFICANTLY MORE PATIENTS RECEIVING UPADACITINIB ACHIEVED ACR50, ACR70 AND CLINICAL REMISSION AT WEEK 12 COMPARED TO PLACEBO\n* ABBVIE - IN SELECT-SUNRISE, UPADACITINIB MET PRIMARY ENDPOINT OF ACR20 ACROSS ALL DOSES AT WEEK 12 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:43:00.000+03:00",
    "crawled": "2018-04-26T20:07:23.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "upadacitinib",
        "meet",
        "primary",
        "key",
        "efficacy",
        "endpoint",
        "phase",
        "rheumatoid",
        "arthritis",
        "study",
        "japanese",
        "patient",
        "abbvie",
        "inc",
        "safety",
        "profile",
        "upadacitinib",
        "consistent",
        "previously",
        "reported",
        "result",
        "new",
        "safety",
        "signal",
        "detected",
        "abbvie",
        "inc",
        "significantly",
        "patient",
        "receiving",
        "upadacitinib",
        "achieved",
        "acr50",
        "acr70",
        "clinical",
        "remission",
        "week",
        "compared",
        "placebo",
        "abbvie",
        "upadacitinib",
        "met",
        "primary",
        "endpoint",
        "acr20",
        "across",
        "dos",
        "week",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}